AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug regimen beat the standard for stem cell transplant complications?
Disease control OngoingThis trial tests whether a drug called cyclophosphamide (PTCY) can prevent graft-versus-host disease (GVHD) better than the current standard, ATG, in patients receiving stem cell transplants from unrelated donors. GVHD is a serious complication where donor immune cells attack the…
Matched conditions: AML
Phase 3 • Sponsor: DKMS gemeinnützige GmbH • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to stop blood cancer relapse after transplant in kids
Disease control OngoingThis study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…
Matched conditions: AML
Phase 2 • Sponsor: Franziska Wachter • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can pressurized oxygen boost cord blood transplants?
Disease control OngoingThis study tests whether giving patients hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) after an umbilical cord blood stem cell transplant helps the donated stem cells grow faster. The trial enrolls people with blood cancers like leukemia or lymphoma who lack …
Matched conditions: AML
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New trial aims to snuff out hidden leukemia before it returns
Disease control OngoingThis early-phase trial tests whether a combination of two drugs, MBG-453 and azacitidine, can eliminate leftover cancer cells in people with acute myeloid leukemia (AML). The goal is to prevent relapse by treating the disease when it is still at a very low level. Only 3 participa…
Matched conditions: AML
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New chemo cocktail aims to boost survival in elderly leukemia patients
Disease control OngoingThis phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regim…
Matched conditions: AML
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo tackles relapsed blood cancers after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in 55 adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that returned after a stem cell transplant. The goal is to find the best dose and see if the treatment…
Matched conditions: AML
Phase 1/2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo targets tough leukemia in early trial
Disease control OngoingThis study tests a new combination of two drugs (gemtuzumab ozogamicin and gilteritinib) for adults with a specific genetic form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial aims to see if the combination is safe and helps control th…
Matched conditions: AML
Phase 2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC